Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:45:31 EDT Wed 01 May 2024
Enter Symbol
or Name
USA
CA



Q:LUMO - LUMOS PHARMA INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
LUMO - Q2.03.01·3.281.53.02+0.155.2278.37829332.76  3.07  2.7254.55  2.4119:59:25Apr 1815 min RT 2¢

Recent Trades - Last 10 of 933
Time ETExPriceChangeVolume
19:59:25Q3.100.291
19:52:27Q3.040.2310
19:44:59Q3.100.291
19:32:49Q3.100.291
19:30:45Q3.100.291
18:36:40Q3.100.2929
18:36:40Q3.070.261,000
18:36:40Q3.050.244,142
18:31:39Q3.110.3050
18:16:27Q3.130.32300

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-18 16:05U:LUMONews ReleaseLumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
2024-03-20 08:00U:LUMONews ReleaseLumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
2024-03-07 16:01U:LUMONews ReleaseLumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
2024-02-26 09:00U:LUMONews ReleaseLumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
2024-02-05 16:05U:LUMONews ReleaseLumos Pharma to Participate in ‚  Oppenheimer ¢ € ™s 34th Annual Healthcare Life Sciences Conference
2024-01-04 16:05U:LUMONews ReleaseLumos Pharma Promotes Pisit ¢ € œDuke ¢ €  Pitukcheewanont, MD to Chief Medical Officer
2023-11-21 16:15U:LUMONews ReleaseLumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
2023-11-20 16:05U:LUMONews ReleaseLumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
2023-11-07 16:35U:LUMONews ReleaseLumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
2023-11-07 16:01U:LUMONews ReleaseLumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
2023-09-26 09:00U:LUMONews ReleaseLumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
2023-09-14 08:00U:LUMONews ReleaseLumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting
2023-09-07 16:34U:LUMONews ReleaseLumos Pharma Announces Participation in Investor Conferences in September
2023-08-22 09:00U:LUMONews ReleaseIndependent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape
2023-08-09 16:01U:LUMONews ReleaseLumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
2023-07-26 09:00U:LUMONews ReleaseLumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023
2023-07-12 08:00U:LUMONews ReleaseLumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit
2023-06-28 16:01U:LUMONews ReleaseLumos Pharma Announces Departure of Chief Medical Officer
2023-06-21 09:00U:LUMONews ReleaseLumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar
2023-05-31 08:00U:LUMONews ReleaseLumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference